Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB5665 : Y-MESO-8D  update : 2024/11/11
CommentRCB5664 Y-MESO-8A, RCB5665 Y-MESO-8D were derived from the same patient.
Comment from the depositorHuman malignant pleural mesothelioma cell line. The primary tumor is a biphasic (predominantly sarcomatoid) tumor tissue. Subcloned from patient's pleural fluid and shows sarcomatoid morphology.
Terms and conditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Cancer Sci 2006 97:387-394) designated by the DEPOSITOR is requested.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor SEKIDO, Yoshitaka
Originator SEKIDO, Yoshitaka
Year of deposit 2022
Original cell Y-MESO-8
Cloning (depositor) Yes
_Date (depositor) 2001
_Method (depositor) ring cloning
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 61 years
Tissue pleural effusion
Primary focus malignant pleural mesothelioma
Case history malignant pleural mesothelioma
Tumor malignant pleural mesothelioma (biphasic (predominantly sarcomatoid)
Metastatic ability Unknown
Classification cancer
Recombinant non-recombinant
Year of origin 2001
Lifespan infinite
Morphology fibroblast-like
Cellosaurus(Expasy) CVCL_5189
deposit info
lot info
Medium Medium List
Culture type Adherent cells Adherent cells
Culture medium RPMI1640 + 10% FBS RPMI1640 + 10% FBS
Antibiotics 1% antimicrobial Free
Passage method 0.25w/v% Trypsin + 1mmol/l EDTA（FUJIFILM 209-16941） 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
Culture information Passage ratio 1 : 5-8 split 1 : 5 split
SC frequency Subculture : 1-2 times/week Subculture : 1-2 times/week
Temperature 37 ℃ 37 ℃
CO2 concentration 5 % 5 %
Freeze medium CELLBANKER CELLBANKER 1
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Mycoplasma (-)
Animal PCR OK
Virus (HIV) (-) Undetected
Virus (HTLV-1) (-)
Virus (HBV) (-)
Virus (HCV) (-)
Virus (EBV) (-)
STR(human) OK
deposit info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8,9 11 12 14,16 7,9 X,Y 11 11,12
lot info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8,9 11 12 14,16 7,9 X,Y 11 11,12
Reference information Reference 21
User's Publication 0


To topTop
Reference
17591  Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A.  Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma  Front Cell Dev Biol  2022  10:945007.  PubMed ID: 35903548   DOI: 10.3389/fcell.2022.945007
16466  Sato T, Mukai S, Ikeda H, Mishiro-Sato E, Akao K, Kobayashi T, Hino O, Shimono W, Shibagaki Y, Hattori S, Sekido Y.  Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation  Mol Cancer Res  2021  19(5):921-931  PubMed ID: 33574130   DOI: 10.1158/1541-7786.MCR-20-0637
16452  Okazaki Y, Misawa N, Akatsuka S, Kohyama N, Sekido Y, Takahashi T, Toyokuni S.  Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats  Cancer Sci  2020  111(4):1180-1192.  PubMed ID: 32080953   DOI: 10.1111/cas.14358
16027  Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation  Oncogene  2018  38(11):1966-1978  PubMed ID: 30401981   DOI: 10.1038/s41388-018-0417-7
16453  Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S.  Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model  Oncotarget  2018  9(26):18494-18509  PubMed ID: 29719620   DOI: 10.18632/oncotarget.24892
16454  Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, Ito F, Saya H, Sekido Y, Toyokuni S.  Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma  Free Radic Biol Med  2017  106:91-99  PubMed ID: 28185919   DOI: 10.1016/j.freeradbiomed.2017.02.011
16467  Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.  Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis  Cancer Lett  2017  385:215-224.  PubMed ID: 27773750   DOI: 10.1016/j.canlet.2016.10.020
16026  Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, Suguro M, Matsuo K, Nakanishi H, Kiyono T, Nakamura S, Osada H, Sekido Y, Seto M, Tsuzuki S.  Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation  Carcinogenesis  2016  37(11):1098-1109  PubMed ID: 27559111   DOI: 10.1093/carcin/bgw084
16468  Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y.  Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells  Cancer Sci  2015  106(8):990-9.  PubMed ID: 26011428   DOI: 10.1111/cas.12698
16469  Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade  Oncogene  2015  34(1):73-83  PubMed ID: 24336325   DOI: 10.1038/onc.2013.528
16455  Chew SH, Okazaki Y, Nagai H, Misawa N, Akatsuka S, Yamashita K, Jiang L, Yamashita Y, Noguchi M, Hosoda K, Sekido Y, Takahashi T, Toyokuni S.  Cancer-promoting role of adipocytes in asbestos-induced mesothelial carcinogenesis through dysregulated adipocytokine production  Carcinogenesis  2014  35(1):164-72  PubMed ID: 23917077   DOI: 10.1093/carcin/bgt267
16456  Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.  Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells  Ann Surg Oncol  2012  19 Suppl 3(Suppl 3):S634-45  PubMed ID: 22086445   DOI: 10.1245/s10434-011-2142-0
16470  Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, Ishiguro F, Osada H, Sekido Y, Yokoi K, Usami N, Shames DS, Kondo M, Gazdar AF, Minna JD, Hasegawa Y.  The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma  Int J Cancer  2012  131(12):2820-31  PubMed ID: 22510946   DOI: 10.1002/ijc.27598
16471  Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes  Oncogene  2012  31(49):5117-22  PubMed ID: 22286761   DOI: 10.1038/onc.2012.5
16472  Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Yokoi K, Osada H, Sekido Y.  Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma  J Thorac Oncol  2012  7(5):890-9  PubMed ID: 22722789   DOI: 10.1097/JTO.0b013e31824af2db
16473  Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, Hida T, Tsujimura T, Osada H, Sekido Y.  TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth  J Exp Med  2012  209(3):479-94  PubMed ID: 22329991   DOI: 10.1084/jem.20111653
16474  Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y.  LATS2 is a tumor suppressor gene of malignant mesothelioma  Cancer Res  2011  71(3):873-83  PubMed ID: 21245096   DOI: 10.1158/0008-5472.CAN-10-2164
16457  Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.  Activation of the PI3K-AKT pathway in human malignant mesothelioma cells  Mol Med Rep  2009  2(2):181-8  PubMed ID: 21475810   DOI: 10.3892/mmr_00000081
16475  Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y.  Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells  Carcinogenesis  2009  30(7):1097-105  PubMed ID: 19380521   DOI: 10.1093/carcin/bgp097
16458  Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y.  Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32  Cancer Sci  2007  98(3):438-46  PubMed ID: 17270034   DOI: 10.1111/j.1349-7006.2006.00386.x
3337  Usami, Noriyasu, Fukui, Takayuki, Kondo, Masashi, Taniguchi, Tetsuo, Yokoyama, Toshihiko, Mori, Shoichi, Yokoi, Kohei, Horio, Yoshitsugu, Shimokata, Kaoru, Sekido, Yoshitaka, Hida, Toyoaki  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.  Cancer Sci  2006  97:387-94  PubMed ID: 16630136   DOI: 10.1111/j.1349-7006.2006.00184.x

To topTop
User's Publication


Back Back Return Top Page